Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin’s Lymphomas: Results of a Japanese Phase II Study
详细信息 查看全文
- 作者：Michinori Ogura (1)
Yasuo Morishima (1)
Yukio Kobayashi (2)
Naokuni Uike (3)
Susumu Sugai (4)
Takaaki Chou (5)
Masaharu Kasai (6)
Ikuo Miura (7)
Tohru Murayama (8)
Yoshihiro Matsuno (9)
Shigeo Nakamura (10)
Shigeo Mori (11)
Yasuo Ohashi (12)
Kensei Tobinai (2) - 关键词：Cladribine ; 2 ; CdA ; Indolent lymphoma ; Phase II study ; Prolonged cytopenia ; Secondary MDS
- 刊名：International Journal of Hematology
- 出版年：2004
- 出版时间：October 2004
- 年：2004
- 卷：80
- 期：3
- 页码：267-277
- 全文大小：125KB
- 参考文献：1. Rohatiner A, Lister TA. Follicular lymphoma. In: Magrath IT, ed. / The Non-Hodgkin’s Lymphomas. London, UK: Oxford University Press; 1997:867-96.
2. Berger F, Felman P, Sonet A, et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. / Blood. 1994;83:2829-835.
3. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. / N Engl J Med. 1984;311:1471-475.
4. Kennedy BJ, Bloomfield CD, Kiang DT, Vosika G, Peterson BA, Theologides A. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. / Cancer. 1978;41:23-8. CrossRef
5. Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O’Connell MJ. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. / J Clin Oncol. 1985;3:769-75.
6. Steward WP, Crowther D, McWilliam LJ, et al. Maintenance chlorambucil after CVP in the management of advanced stage, lowgrade histologic type non-Hodgkin’s lymphoma: a randomized prospective study with an assessment of prognostic factors. / Cancer. 1988;61:441-47. CrossRef
7. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. / J Clin Oncol. 1993;11:644-51.
8. Rosenberg SA. The low-grade non-Hodgkin’s lymphomas: challenges and opportunities. / J Clin Oncol. 1985;3:299-10.
9. Kondo E, Ogura M, Kagami Y, et al. Assessment of prognostic factors in follicular lymphoma patients. / Int J Hematol. 2001;73:363-68. CrossRef
10. Beutler E. Cladribine (2-chlorodeoxyadenosine). / Lancet. 1992;340:952-56. CrossRef
11. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward restive and proliferative human lymphocytes. / Blood. 1983;62:737-43.
12. Piro LD, Carrera CI, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. / Blood. 1988;72:1069-073.
13. Juliusson G, Liliemark J. High complete remission rate of 2-chloro-2-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. / J Clin Oncol. 1993;11:679-89.
14. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. / J Clin Oncol. 1995;13:570-74.
15. Tallman MS, Hakimian D, Zanzig C, et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. / J Clin Oncol. 1995;13:983-38.
16. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2 chlorodeoxyadenosine. / N Engl J Med. 1990;322:1117-121.
17. Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). / Blood. 1992;79:882-87.
18. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. / J Clin Oncol. 1992;10:371-77.
19. Hoffman M,Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma. / J Clin Oncol. 1994;12:788-92.
20. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin’s lymphoma. / Blood. 1995;86:1710-716.
21. Tobinai K, Ogura M, Hotta T, et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies: Cladribine Study Group. / Jpn J Clin Oncol. 1997;27:146-53. CrossRef
22. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. / Blood. 1994;84:1361-392.
23. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ. Antibody L26 recognizes an intracellular episode on the B-cell-associated CD20 antigen. / Am J Pathol. 1990;136:1215-222.
24. Banno S, Yoshikawa K, Nakamura S, et al. Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus. / Jpn J Cancer Res. 1994;85:918-26.
25. Nakamura S, Seto M, Banno S, et al. Immunohistochemical analysis on the cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. / Jpn J Cancer Res. 1994;85:1270-279.
26. World Health Organization. / WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
27. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria ofthe Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group. / Jpn J Clin Oncol. 1993;23:250-57.
28. Brookmeyer R. A confidence interval for the median survival time. / Biometrics. 1982;38:29-1. CrossRef
29. Kong LR, Huang CF, Hakimian D, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin’s lymphoma. / Cancer. 1998;82:957-64. CrossRef
30. Hickish T, Serefinowski P, Cunningham D, et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. / Br J Cancer. 1993;67:139-43.
31. Robak T, Gora-Tybor J, Krykowski E, et al. Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin’s lymphoma. / Leuk Lymphoma. 1997;26:99-05. CrossRef
32. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. / J Clin Oncol. 2002;20:3872-877. CrossRef
33. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. / Blood. 1995;85:1075-082.
34. Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantlecell and low-grade non-Hodgkin’s lymphoma. / Eur J Cancer. 2002;38:1739-746. CrossRef
35. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. / Blood. 1992;80:587-92.
36. Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. / JAMA. 1975;232:267-69. CrossRef
37. Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancer in patients with chronic lymphocytic leukemia: a possible immunologic mechanism. / J Natl Cancer Inst. 1978;61:337-40.
38. Jacobs RH,Vokes EE, Golomb HM. Second malignancies in hairy cell leukemia. / Cancer. 1985;56:1462-467. CrossRef
39. Cheson BD,Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. / J Clin Oncol. 1999;17:2454-460.
40. Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. / J Clin Oncol. 1993;11:1039-045.
41. Darrington DL,Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. / J Clin Oncol. 1994;12:2527-534.
42. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. / Blood. 1994;83:3780-786.
43. Pederson-Bjergaard J. Radiotherapy and chemotherapy-induced myelodysplasia and acute myeloid leukemia: a review. / Leuk Res. 1992;16:61-5. CrossRef
44. Travis LB,Weeks J, Curtis RE, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin’s lymphoma. / J Clin Oncol. 1996;14:565-71.
45. Zulian GB, Jotterand Bellomo M, Cabrol C, Beris P, Mermillod B, Alberto P. Etoposide and secondary haematological malignancies: coincidence or causality? / Ann Oncol. 1993;4:559-66.
46. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). / Eur J Haematol. 1991;47:17-7. CrossRef
47. Robak T, Gora-Tybor J, Lech-Maranda E, Blonski JZ, Kasznicki M. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. / Eur J Haematol. 2001;66:188-94. CrossRef
48. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. / Blood. 1997;90:2188-195.
49. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. / J Clin Oncol. 1998;16:2825-833.
50. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. / Haematologica. 2002;87:33-3.. - 作者单位：Michinori Ogura (1)
Yasuo Morishima (1)
Yukio Kobayashi (2)
Naokuni Uike (3)
Susumu Sugai (4)
Takaaki Chou (5)
Masaharu Kasai (6)
Ikuo Miura (7)
Tohru Murayama (8)
Yoshihiro Matsuno (9)
Shigeo Nakamura (10)
Shigeo Mori (11)
Yasuo Ohashi (12)
Kensei Tobinai (2)
1. Department of Hematology and Chemotherapy, Aichi Cancer Center, Kanokoden 1-1, Chikusa-ku, 464-8681, Nagoya, Aichi, Japan
2. Hematology Division, National Cancer Center Hospital, Tokyo
3. Department of Hematology, National Kyushu Cancer Center Hospital, Fukuoka
4. Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa
5. Department of Hematology, Niigata Cancer Center Hospital, Niigata
6. Department of Hematology, Sapporo Hokuyu Hospital, Hokkaido
7. Third Department of Internal Medicine, Akita University School of Medicine, Akita
8. Department of Hematology, Hyogo Medical Center for Adults, Hyogo
9. Clinical Laboratory Division, National Cancer Center Hospital, Tokyo
10. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi
11. Department of Pathology, Institute of Medical Science, University of Tokyo, Tokyo
12. Biostatistics Sciences, School of Health Science and Nursing Biostatistics, University of Tokyo, Tokyo, Japan
文摘
We conducted a phase II study to evaluate the efficacy and safety of cladribine (2-chlorodeoxyadenosine [2-CdA]) for patients with refractory or relapsed indolent B-cell lymphoma or mycosis fungoides. Forty-five patients were enrolled, and 43 patients, including 34 with follicular lymphoma, were eligible. 2-CdA was given by continuous intravenous infusion at a dose of 0.09 mg/kg daily for 7 consecutive days, and this schedule was repeated every 4 weeks up to a maximum of 6 cycles. The overall and complete response rates were 58.1% (25/43; 90% confidence interval, 44.5%-70.9%) and 14.0% (6/43), respectively. The disease progression-free proportions of all 43 eligible and all 25 responding patients at 2 years were 30.3% and 48.1%, respectively. Neutropenia and thrombocytopenia of grade 3 or 4 were observed in 53.3% and 37.8% of patients, respectively, with prolonged cytopenia observed in patients with increased numbers of treatment cycles. Nonhematologic toxicities of grade 3 or greater included diarrhea, arrhythmia, malaise, and gastrointestinal bleeding in 1 patient each, an increase in glutamic-pyruvic transaminase level in 2 patients, and infection in 5 patients. Two treatment-related deaths were observed. Four patients developed myelodysplastic syndrome (MDS) at 13 months to 2 years after completion of the 2-CdA treatments. 2-CdA is an active agent with acceptable toxicity for refractory or relapsed indolent lymphoma; however, prolonged myelosuppression and the potential development of MDS should be carefully monitored.